Depomed Announces Initiation of Phase 2 Clinical Study in Parkinson's Disease

Symbols: DEPO
Posted in: News, FDA
Share

Depomed, Inc. (Nasdaq: DEPO) today announced that it has initiated a Phase 2 clinical trial of DM-1992, Depomed's novel gastric-retentive, extended-release formulation of carbidopa/levodopa, in patients with advanced Parkinson's disease with motor fluctuations.


 
 
< Previous
Fusion-IO Reports Q2 EPS $0.05; Revenues $84.1M
Next >
Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust